Literature DB >> 9314445

Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus.

F P Kroon1, J T van Dissel, G T Rijkers, J Labadie, R van Furth.   

Abstract

A prospective study of antibody production by adults infected with human immunodeficiency virus (HIV) after vaccination with tetanus toxoid-conjugated Haemophilus influenzae type b (Hib) vaccine was conducted. Concentrations of antibodies to the two immunogenic components of the vaccine (i.e., polyribosylribitolphosphate [PRP] and tetanus toxin) were determined. Individuals were divided into three groups according to the CD4+ T lymphocyte count: group 1, < or =100 x 10(6)/L; group 2, 101-300 x 10(6)/L; and group 3, >300 x 10(6)/L. After vaccination, concentrations of IgM and IgG antibodies to PRP were significantly lower in group 1 than in the other patient groups and controls. A CD4+ T lymphocyte count of <100 x 10(6)/L and an impaired proliferative response of lymphocytes to monoclonal antibody to CD3 were independently associated with a less than threefold increase in concentrations of IgG antibody to PRP. Analysis of IgG subclasses demonstrated that the production of IgG1 antibodies was predominantly affected. Postvaccination concentrations of antibody to tetanus toxin were significantly lower in group 1 than in group 3 and controls. Both prevaccination and postvaccination concentrations of antibody to tetanus toxin were not correlated with the magnitude of the response of antibody to PRP. We conclude that HIV-infected individuals with CD4+ T Iymphocyte counts of <100 x 10(6)/L demonstrate an impaired antibody response after vaccination with conjugated Hib vaccine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314445     DOI: 10.1086/513750

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.

Authors:  A Payeras; P Martinez; J Milà; M Riera; A Pareja; J Casal; N Matamoros
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

2.  Clostridium difficile in a HIV-infected cohort: incidence, risk factors, and clinical outcomes.

Authors:  Charles F Haines; Richard D Moore; John G Bartlett; Cynthia L Sears; Sara E Cosgrove; Karen Carroll; Kelly A Gebo
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

3.  Vaccination in HIV-infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.663

4.  Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients.

Authors:  Kpandja Djawe; Laurence Huang; Kieran R Daly; Linda Levin; Judy Koch; Alexandra Schwartzman; Serena Fong; Brenna Roth; Anuradha Subramanian; Katherine Grieco; Leah Jarlsberg; Peter D Walzer
Journal:  PLoS One       Date:  2010-12-09       Impact factor: 3.240

5.  Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.

Authors:  Karen Yao; Susan Gagnon; Nahid Akhyani; Elizabeth Williams; Julie Fotheringham; Elliot Frohman; Olaf Stuve; Nancy Monson; Michael K Racke; Steven Jacobson
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

6.  Durability of Antibody Response after Primary Pneumococcal Double-Dose Prime-Boost Vaccination in Adult Kidney Transplant Recipients and Candidates: 18-Month Follow-Up in a Non-Blinded, Randomised Clinical Trial.

Authors:  Lykke Larsen; Claus Bistrup; Søren Schwartz Sørensen; Lene Boesby; Charlotte Sværke Jørgensen; Christian Nielsen; Isik Somuncu Johansen
Journal:  Vaccines (Basel)       Date:  2022-07-07

7.  Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.

Authors:  Robert J Blount; Leah G Jarlsberg; Kieran R Daly; William Worodria; J Lucian Davis; Adithya Cattamanchi; Kpandja Djawe; Alfred Andama; Judith Koch; Peter D Walzer; Laurence Huang
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.